García Romero, NoemíPalacín Aliana, I.Madurga Lacalle, RodrigoCarrión Navarro, JosefaEsteban Rubio, S.Jiménez, B.Collazo, A.Pérez Rodríguez, F.Ortiz de Mendivil, A.Fernández Carballal, C.García Duque, s.Diamantopoulos-Fernández, J.Belda Iniesta, C.Prat Acín, R.Sánchez Gómez, P.Calvo, E.Ayuso Sacido, Ángel2020-10-222020-10-2220201741-7015http://hdl.handle.net/10641/2022Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.engAtribución-NoComercial-SinDerivadas 3.0 EspañaVEGFAAngiogenesisBevacizumabGlioblastomaNeovasculogenesisjournal articleopen access10.1186/s12916-020-01610-0